Shenchen Weiguang Biological Products

Shenzhen Weiguang Biological Products is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacture of plasma-derived medicinal products. Founded in 1985 and headquartered in Shenzhen, the company is a key player in the domestic blood products market, offering a comprehensive portfolio that includes human albumin, intravenous immunoglobulins, and various coagulation factors. In 2023, the company became a subsidiary of Sinopharm (China National Pharmaceutical Group), integrating into one of the world's largest healthcare conglomerates. Weiguang Biological operates state-of-the-art GMP manufacturing facilities and several plasma collection centers, ensuring a stable supply of high-quality biological therapies. The company is also expanding its R&D pipeline into recombinant proteins and advanced blood components to address unmet needs in hematology and immunology.